Diffuse large B Cell lymphoma (DLBCL) is a type aggressive non-Hodgkin Lymphoma (NHL). About 30% of patients who diagnosed NHL is DLBCL in both male and female. It is divided into 3 major types which distinct by immunological characteristics. It shall shows variable spectrum of prognosis and response to the treatment due to gene expression variability. Nowadays Rituximab is the gold standard treatment of NHL which is targeting monoclonal antibody of CD20 and it also shows good prognosis to DLBCL. Rituximab containing chemotherapy regimen like R-CHOP shows relatively good response to DLBCL compare to pre-rituximab era and in rituximab era, overall relative survival rate was significantly increased compare to pre-rituximab era. Recently, further study about the treatment that adjusted to the gene mutation is in progress.